You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Epigenomics terminated its collaboration with China's BioChain for the licensing of the septin9 marker and exclusive Chinese distribution rights for Epi proColon.
The test uses qPCR to measure the methylation level of three bladder cancer-specific biomarkers in patient urine samples.
Galaxy has licensed IP from Proteome Sciences for the development of a test for the diagnosis and timing of stroke onset to help inform treatment decisions.
Genfit's assay will be deployed through Covance's central laboratories to validate its use to better identify and characterize patients with the liver disease.
The New York Department of Health-certified tests are based on proprietary algorithms licensed from Columbia University, which offers them in the US.
Luminex has licensed the XCR Diagnostics Xtreme Chain Reaction nucleic acid amplification technology for an undisclosed amount.
New England Biolabs is using Avacta's affimers with a development-stage research and diagnostic assay that could launch as early as next year.
Precision Pathology will develop the CyPath Lung test for early-stage detection of lung cancer as an LDT for commercial sale by the first-quarter of 2019.
Siemens' Atellica BRAHMS PCT assay received clearance from the US Food and Drug Administration on July 16, which the company announced in August.
Fleury will integrate IDbyDNA's Explify platform into its own laboratory workflow and develop a full suite of Explify-based clinical testing.